Mirtazapină Aurobindo (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapină Aurobindo, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is used to treat major depressive disorder in adult patients. GNH USA supplies Mirtazapină Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for major depressive disorder, a condition affecting mood and functioning. It helps improve depressive symptoms and overall quality of life.

- Major depressive disorder: alleviates depressive symptoms and improves mood. - Treatment‑resistant depression: may be added when first‑line agents are insufficient. - Co‑morbid anxiety in depression: can reduce anxiety symptoms associated with depression.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Hepatotoxicity or liver injury - Seizures in predisposed individuals

When prescribing mirtazapine, clinicians should consider several safety aspects. - Pregnancy: Category B; use only if potential benefit justifies the risk. - Elderly patients: increased sensitivity to sedation and orthostatic hypotension. - Discontinuation: avoid abrupt stopping to reduce withdrawal symptoms. - Weight monitoring: assess for significant appetite increase and weight gain. - Suicidality: monitor for emergent suicidal ideation, particularly at treatment initiation. - Store at room temperature: keep in the original container, protect from moisture.

Mirtazapine can interact with various medications, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis; discontinue MAOIs at least 14 days prior. - Other CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression. - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Antihistamines: may enhance sedative effects. - Alcohol: can intensify central nervous system depression.